<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125341</url>
  </required_header>
  <id_info>
    <org_study_id>CAN106-01001</org_study_id>
    <nct_id>NCT05125341</nct_id>
  </id_info>
  <brief_title>Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China</brief_title>
  <official_title>Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CANbridge Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CANbridge Life Sciences Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center observational study conducted in adult patients with paroxysmal&#xD;
      nocturnal hemoglobinuria of high-risk hemolysis.&#xD;
&#xD;
      This observational study consists of two parts, one part is retrospective study which aims to&#xD;
      collect medical chart data to calculate the mean change or mean incidence rates of LDH,&#xD;
      hemoglobin, PNH-related symptoms and PNH-related events over 6 months.&#xD;
&#xD;
      The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest&#xD;
      follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference&#xD;
      between eligible PNH patients and healthy people and to explore the related clinical factor&#xD;
      influencing high-level total C5 using logistic regression model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the mean change of LDH</measure>
    <time_frame>6 months</time_frame>
    <description>the mean change of LDH over 6 months</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria, Natural History Study</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria;&#xD;
&#xD;
          2. Age ≥ 18 years old;&#xD;
&#xD;
          3. PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%;&#xD;
&#xD;
          4. LDH≥1.5 ULN;&#xD;
&#xD;
          5. Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal&#xD;
             pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis),&#xD;
             dysphagia, erectile dysfunction;&#xD;
&#xD;
          6. Transfusion-dependent PNH patients;&#xD;
&#xD;
          7. There are at least 6 months consecutive data of diagnosis and treatment after the data&#xD;
             collection time point;&#xD;
&#xD;
          8. Patients agreed to participate in the study by signing informed consent or giving oral&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in&#xD;
             the past;&#xD;
&#xD;
          2. Patients have received bone marrow transplantation;&#xD;
&#xD;
          3. platelet count &lt;30*10 9/L or absolute neutrophil count &lt;0.5*10 9/L;&#xD;
&#xD;
          4. Patients have clinically significant heart, liver, or lung diseases, or have related&#xD;
             medical history.&#xD;
&#xD;
          5. Patients have comorbidities of rheumatoid disease, HIV infection, active HBV&#xD;
             infection, HCV infection and other diseases that affect the body's immune function;&#xD;
&#xD;
          6. Severe missing data in the records of diagnosis and treatment after the data&#xD;
             collection time point;&#xD;
&#xD;
          7. Other patients who are not suitable to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

